One of the problems that has slowed the development and approval of new anticancer
therapies is the lack of preclinical models that can be used to identify key molecular, cellular …

Every year, cancer claims millions of lives around the globe. Unfortunately, model systems
that accurately mimic human oncology–a requirement for the development of more effective …

Cancer remains one of the leading causes of death, albeit enormous efforts to cure the
disease. To overcome the major challenges in cancer therapy, we need to have a better …

The transition to increasingly sophisticated microfluidic systems has led to the emergence of
“organ-on-chip” technology that can faithfully recapitulate organ-level function. Given the …

The approval of anticancer therapeutic strategies is still slowed down by the lack of models
able to faithfully reproduce in vivo cancer physiology. On one hand, the conventional in vitro …

Simple Summary Organoids, also known as self-organized 3D organ-like clusters, represent
almost a physiological system for studying cells, stem cells, tissues, and diseases, especially …

The ideal in vitro recreation of the micro-tumor niche—although much needed for a better
understanding of cancer etiology and development of better anticancer therapies—is highly …

Over the past six decades the inflation-adjusted cost to bring a new drug to market has been
increasing constantly and doubles every 9 years–now reaching in excess of $2.5 billion …

The failure of animal models to predict therapeutic responses in humans is a major problem
that also brings into question their use for basic research. Organ-on-a-chip (organ chip) …

Tumor cell heterogeneity with distinct phenotypes, genotypes, and epigenetic states as well
as the complex tumor microenvironment is major challenges for cancer diagnosis and …